Logo

Argonaut Shareholders Approve Purchase by Biotage of Portions of Company

Jun 02, 2005

NEW YORK, June 2 (GenomeWeb News) - A majority of Argonaut's shareholders have approved the acquisition of parts of the company by Biotage, according to a statement the companies released today.

 

Those portions -- Argonaut's reagents and process instruments business -- will officially be part of Biotage on June 3. Biotage will pay 155 MSEK ($20.9 million) for the components.

 

The acquisition is aimed at strengthening Biotage's offering in medicinal chemistry, according to Jeff Bork, president and CEO.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.